- Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response
- Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting
- Precigen Reports First Quarter 2024 Financial Results and Business Updates
- Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting
- Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
- Actym Therapeutics Appoints Thomas Smart as CEO
More ▼
Key statistics
On Wednesday, Precigen Inc (PGEN:NSQ) closed at 1.47, -21.80% below its 52-week high of 1.88, set on Aug 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.51 |
---|---|
High | 1.53 |
Low | 1.46 |
Bid | 1.48 |
Offer | 1.49 |
Previous close | 1.49 |
Average volume | 773.94k |
---|---|
Shares outstanding | 252.42m |
Free float | 223.44m |
P/E (TTM) | -- |
Market cap | 376.11m USD |
EPS (TTM) | -0.3896 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼